Lonza will produce clinical and commercial supplies of Osiris’ adult stem cell product.

Lonza signed a clinical and commercial manufacturing agreement with Osiris Therapeutics for Prochymal®, Osiris’ adult stem cell therapy. Prochymal is being evaluated in Phase III trials for acute and steroid-refractory graft-versus-host disease and Crohn’s disease.

Lonza also announced the construction of new facilities including the first commercial-scale allogeneic cGMP manufacturing plant and additional capacity to produce cGMP-grade cell culture media for therapeutic applications. This will provide Lonza the capacity to manufacture the tens of billions of cells per day needed to support its clients’ commercialization efforts, say Lonza officials.

Previous articleCase Western, Copernicus Therapeutics, and Polygenix Are Recipients of $3.9M from the Ohio Department of Development
Next articleLack of Protein in Neural Stem Cell Linked to Rett Syndrome